Human rhinovirus (HRV) antibodies
US8822651B2 · kind B2 · utility
0Cited by
63References
48Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Aug 28, 2012 |
| Grant date | Sep 2, 2014 |
| Priority date | — |
| Expiry date | Aug 28, 2032 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2770/32734
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides isolated fully human monoclonal anti-HRV antibodies, as well as method of making and using these antibodies. Anti-HRV antibodies of the invention prevent or treat subjects having HRV-infections, and related diseases, including, but not limited to, the common cold, nasopharyngitis, croup, pneumonia, bronchiolitis, asthma, chronic obstructive pulmonary disease (COPD), sinusitis, bacterial superinfection, and cystic fibrosis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.